| Name | Title | Contact Details |
|---|
Scientek Technology Corp. is a Delta, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Staino is a Long Eddy, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Repro-Med Systems, Inc., operating as RMS Medical products, is a leading developer and manufacturer of medical devices and supplies. Repro-Med was incorporated in March, 1980. Its stock is publicly traded in the over-the-counter market and is quoted through the National Daily Quotation Service. Its stock symbol is REPR. The company maintains offices, manufacturing facilities, and warehouse space in Chester, New York. Devices and supplies manufactured and sold by RMS Medical Products are subject to Food and Drug Administration regulation. Our manufacturing facilities and record-keeping must meet FDA standards, and are subject to periodic FDA inspection. In addition, the company's plant is certified by the appropriate ISO international standards for quality in product development, manufacturing, distribution and customer support of its medical devices. RMS manufactures medical devices used in emergency care, hospital settings, nursing homes, other medical facilities and home care. The Company's principal products are the FREEDOM60 Syringe Infusion System and the RES-Q-VAC Emergency Medical Suction System. In 2011, the company received FDA approval to market in the U.S. it's HIgH-Flo RMS Subcutaneous Needle Sets. Since 1986, the company has owned and marketed the Gyneco product line which includes the Masterson Endometrial Biopsy Kit used for in-office biopsy sampling procedures, and the Thermal Cautery System used for tubal ligation procedures. RMS maintains its own sales staff in addition to selling its products through distributors in the U.S. and many other countries. It regularly exhibits at both national and international trade shows. The company holds a number of patents related to products it has developed and is manufacturing. Because Repro-Med Systems, Inc., is a public company, it must comply with financial reporting and other regulations established by the Securities and Exchange Commission.
Improving healthcare through innovative technology is at the core of Intelerad`s work. Our scalable medical imaging platform connects clinicians to a powerful imaging ecosystem that is fast, smart and tapped into the data they need, no matter their location. We`re focused on delivering a best-in-class medical image management solution that improves provider efficiency, decreases the cost of healthcare, and improves the overall health of populations.
InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. The Infrascanner enables clinicians to detect effectively, conveniently, and accurately intracranial bleeding in patients with head trauma. Intracranial hematomas are an important treatable cause of secondary brain injury in patients with head trauma. Recent statistics from Iraq shows that 30% of all wounded in action have head injuries; of them 40% have brain hematomas. Dr. Britton Chance (University of Pennsylvania) and Dr. Claudia Robertson (Baylor College of Medicine) invented a NIR system for detection of brain Hematomas and tested it successfully in 305 patients in Baylor. An entrepreneurial team formed a company around this technology in Collaboration with Drexel University and won the Wharton Business Plan competition in April 2004 and the second prize at the global business plan competition in Singapore in October 2004. Office of Naval Research funded the company in May 2004. The company also attracted $1.5M in funding from BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania, from Ben Franklin Technology Partners of Southeastern Pennsylvania, and from Philadelphia Industrial Development Corporation. A multicenter clinical study to support an FDA submission started in July 2006, and on February 2008 an application was submitted to the FDA. After 4 years of review, the FDA cleared Infrascanner Model 1000 as a DeNovo medical technology in December 2011. In January 2013 the FDA cleared the 510(k) of Infrascanner Model 2000.